Tripep reports positive results from its ongoing ChronVac-C® study

Tripep reports positive results from its ongoing ChronVac-C® study

Tripep can today report on preliminary results from the first patient in the
middle dose group which now has completed the treatment against hepatitis C
virus infection in the ongoing open study with the therapeutic vaccine
ChronVac-C®. Samples taken before, during and after treatment show that the
viral levels in blood successively decreased with more than 95 percent during
treatment.

ChronVac-C® is a therapeutic vaccine, i.e. it is given to individuals already
infected with the hepatitis C virus with the aim to clear the infection by
boosting the immune response against the virus. Tripep's ChronVac-C® vaccine is
injected in a muscle with Inovio's Medpulser® DDS.

”Previously, we have shown that ChronVac-C® treatment activates immune responses
in the patients belonging to the lowest dose group. It's rewarding to conclude
that we also have clear effects on the viral replication in the first patient
receiving the intermediate dose - the standard by which the effect of antiviral
therapies are measured today”, says Tripep's CEO Jan Nilsson.

”Hepatitis C is a widely spread disease that in more than half of the patients
results in a chronic liver inflammation and a risk for liver cancer or liver
cirrhosis. Currently we lack efficacious pharmaceuticals for the 50 per cent of
patients who doesn't response to treatment available today. Based on the massive
medical need, it's fantastic to see significantly decreased viral levels already
in the middle dose group, and it's going to be very interesting to following
further patients receiving treatment, says Professor Ola Weiland who is the
principle investigator of the study at Karolinska University Hospital.

The total market for therapies against hepatitis C infections is according to
Rodman&Renshaw estimated to be over 4 billion dollars 2008 and is expected to
grow to more than 8 billion dollars by 2013. 

For more information, please contact:
Jan Nilsson, CEO, Tripep AB		                         
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63               
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se		                         

 About Tripep
Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's website: www.tripep.se.

About the ChronVac-C® study
The study is conducted at the Infectious Disease Clinic and the Center for
Gastroenterology at the Karolinska University Hospital in Huddinge and Solna,
respectively and entails totally 12 patients divided into three dose groups with
increasing doses of ChronVac-C®. Each patient receives four ChronVac-C®
vaccinations one month apart. After the last vaccination the patients are
followed for another six months. The analyzed patients in the lowest dose group
has developed a T cell response to hepatitis C. The now reported patient is the
first who has completed treatment in the intermediate dose group.  The main
purpose of the study is safety and this far no expected adverse events have been
recorded. The secondary aim is to determine the immunogenicity and the tertiary
aim is to monitor effects on the viral replication. Currently, seven patients
are undergoing treatment.